EDWARDS LIFESCIENCES TECHNOLOGY SARL
2 recall(s) on record — most severe on record: Class II.
Activity by year
- Recalls (2)
- Inspections (1)
Devices registered here (1)
- Catheter, EmbolectomyProduct code DXE (opens in a new tab) · Class II · Cardiovascular · 21 CFR 870.5150
Recalls & enforcement
- Class IIOngoing2026-08-11Due to incorrect switching of Channel 1 and 2 on the module and flag labels on the tissue oximetry cables.
- Class IIOngoing2026-04-08Catheters may, due to a manufacturing process and material changes, leak/break from the (blue) proximal injectate lumen hub, which may lead to infection, medication loss, and/or blood loss.
FDA inspections (1)
- VAI2019-06-11Voluntary Action Indicated · Compliance: Devices · citations posted
Source: U.S. FDA Inspections Dashboard (opens in a new tab) (device inspection classifications, 2016–present). Data as of 2026-10-06. The dashboard profile can take several seconds to load.
Related
- All facilities operated by Becton, Dickinson and Company
- BECTON, DICKINSON AND COMPANY (CA)
- CCT Critical Care Technologies, S.R.L. Also Trading As Edwards Lifesciences AG (DO)
- Edwards Lifesciences Holding B.V. (NL)
Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this facility record at FDA → (opens in a new tab)
Cite this record
RegWarden. “EDWARDS LIFESCIENCES TECHNOLOGY SARL (FEI 2648045) — FDA facility record.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/facility/2648045-edwards-lifesciences-technology-sarl/
Alerts for EDWARDS LIFESCIENCES TECHNOLOGY SARL
Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.
Want a one-page facility brief?
A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.